ABIONYX Pharma SA (ABNX.PA)
EUR 1.25
(2.46%)
EUR 1.25
(2.46%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.69 Million | -3.35 Million | -6.69 Million | -599 Thousand | -3.95 Million | -6 Million |
| Net Income | -3.51 Million | -4.2 Million | -5.82 Million | -1.88 Million | 1.84 Million | -6.3 Million |
| Depreciation & Amortization | -160 Thousand | 135 Thousand | 119 Thousand | 22 Thousand | 13 Thousand | 39 Thousand |
| Deferred income taxes | - | - | -815 Thousand | -98 Thousand | -4.95 Million | 1.18 Million |
| Stock-based compensation | 20 Thousand | 506 Thousand | 815 Thousand | 98 Thousand | 98 Thousand | 33 Thousand |
| Change in working capital | 538 Thousand | 97 Thousand | -1.74 Million | 2.13 Million | -1.3 Million | -316 Thousand |
| Other non-cash items | -1.18 Million | 109 Thousand | 755 Thousand | -865 Thousand | 351 Thousand | -638 Thousand |
| Investing Cash Flow | -130 Thousand | -175 Thousand | 1.33 Million | -125 Thousand | - | -10 Thousand |
| Investments in PPE | -130 Thousand | -175 Thousand | -166 Thousand | -148 Thousand | - | -23 Thousand |
| Acquisitions | - | - | 1.5 Million | 23 Thousand | - | 13 Thousand |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -100 Thousand | -10 Thousand | 1.5 Million | -22 Thousand | - | 13 Thousand |
| Financing Cash Flow | 3.88 Million | -194 Thousand | 3.97 Million | 1.54 Million | 823 Thousand | 1.19 Million |
| Debt repayment | -300 Thousand | -236 Thousand | -19 Thousand | -200 Thousand | -400 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -65 Thousand | -89 Thousand | - | - |
| Common Stock Issuance | 4.18 Million | 42 Thousand | 4.05 Million | 1.83 Million | 973 Thousand | 1.19 Million |
| Other Financing Activities | 3.9 Million | -200 Thousand | 3.97 Million | 1.54 Million | 250 Thousand | 1.19 Million |
| Accounts receivables | 384 Thousand | 36 Thousand | -95 Thousand | - | - | - |
| Accounts payables | - | -36 Thousand | 95 Thousand | 1.21 Million | -837 Thousand | -575 Thousand |
| Inventory | -80 Thousand | 30 Thousand | 6000.00 | - | - | - |
| Other working capital | 234 Thousand | 67 Thousand | -1.75 Million | 915 Thousand | -467 Thousand | 259 Thousand |
| Cash at beginning of period | 4.04 Million | 7.77 Million | 9.15 Million | 8.33 Million | 11.45 Million | 16.27 Million |
| Cash at end of period | 4.1 Million | 4.04 Million | 7.77 Million | 9.15 Million | 8.33 Million | 11.45 Million |
| Capital Expenditure | -130 Thousand | -175 Thousand | -166 Thousand | -148 Thousand | - | -23 Thousand |
| Effect of forex changes on cash | -44 Thousand | - | - | - | - | 1000.00 |
| Net cash flow / Change in cash | 58 Thousand | -3.72 Million | -1.38 Million | 823 Thousand | -3.12 Million | -4.81 Million |
| Free Cash Flow | -3.82 Million | -3.53 Million | -6.85 Million | -747 Thousand | -3.95 Million | -6.02 Million |
| Breakdown | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -2.08 Million | -3.51 Million | -635 Thousand | -635 Thousand | -2.24 Million | -1.12 Million |
| Depreciation & Amortization | 205 Thousand | -160 Thousand | 33 Thousand | 33 Thousand | 255 Thousand | 37.5 Thousand |
| Deferred income taxes | - | - | - | - | -447 Thousand | - |
| Stock-based compensation | - | 20 Thousand | 73 Thousand | 73 Thousand | -63 Thousand | -63 Thousand |
| Change in working capital | -80 Thousand | 538 Thousand | 377 Thousand | 377 Thousand | -216 Thousand | -108 Thousand |
| Other non-cash items | 89 Thousand | -1.18 Million | -427.5 Thousand | -427.5 Thousand | 180 Thousand | -12 Thousand |
| Investing Cash Flow | -27 Thousand | -130 Thousand | -29.5 Thousand | -29.5 Thousand | -71 Thousand | -35.5 Thousand |
| Investments in PPE | -23 Thousand | -130 Thousand | -18 Thousand | -18 Thousand | -71 Thousand | -34 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | -100 Thousand | -11.5 Thousand | -11.5 Thousand | -1500.00 | -1500.00 |
| Financing Cash Flow | 3.1 Million | 3.88 Million | 1.69 Million | 1.69 Million | 494 Thousand | 247 Thousand |
| Debt repayment | -245 Thousand | -300 Thousand | -781 Thousand | - | -481 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -12 Thousand | - | -6500.00 | -6500.00 | - | - |
| Common Stock Issuance | 3.36 Million | 4.18 Million | 4.17 Million | - | 13 Thousand | - |
| Other Financing Activities | - | 3.9 Million | 1.69 Million | 1.69 Million | 247 Thousand | 247 Thousand |
| Accounts receivables | - | 384 Thousand | 192 Thousand | 192 Thousand | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | -80 Thousand | -40 Thousand | -40 Thousand | - | - |
| Other working capital | -80 Thousand | 234 Thousand | 225 Thousand | 225 Thousand | -108 Thousand | -108 Thousand |
| Cash at beginning of period | 4.1 Million | 4.04 Million | 1.93 Million | 21 Thousand | 4.04 Million | - |
| Cash at end of period | 5.3 Million | 4.1 Million | 4.1 Million | 1.1 Million | 1.93 Million | -1.05 Million |
| Capital Expenditure | -23 Thousand | -130 Thousand | -18 Thousand | -18 Thousand | -71 Thousand | -34 Thousand |
| Effect of forex changes on cash | - | -44 Thousand | - | - | 4000.00 | - |
| Net cash flow / Change in cash | 1.2 Million | 58 Thousand | 2.17 Million | 1.08 Million | -2.11 Million | -1.05 Million |
| Free Cash Flow | -1.89 Million | -3.82 Million | -597.5 Thousand | -597.5 Thousand | -2.61 Million | -1.3 Million |
FHB
MLONL
603690
WSSTF
NCTKY
002349